LLY

1,065.38

+0.03%↑

JNJ

208.01

-1.23%↓

ABBV

224.28

-0.28%↓

UNH

331.13

+1.25%↑

AZN

90.81

+0.46%↑

LLY

1,065.38

+0.03%↑

JNJ

208.01

-1.23%↓

ABBV

224.28

-0.28%↓

UNH

331.13

+1.25%↑

AZN

90.81

+0.46%↑

LLY

1,065.38

+0.03%↑

JNJ

208.01

-1.23%↓

ABBV

224.28

-0.28%↓

UNH

331.13

+1.25%↑

AZN

90.81

+0.46%↑

LLY

1,065.38

+0.03%↑

JNJ

208.01

-1.23%↓

ABBV

224.28

-0.28%↓

UNH

331.13

+1.25%↑

AZN

90.81

+0.46%↑

LLY

1,065.38

+0.03%↑

JNJ

208.01

-1.23%↓

ABBV

224.28

-0.28%↓

UNH

331.13

+1.25%↑

AZN

90.81

+0.46%↑

Kodu・Aktsiate loetelu・Pulse Biosciences Inc

Pulse Biosciences Inc

Suletud

SektorTervishoid

14.35 0.84

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

13.96

Max

14.54

Põhinäitajad
By Trading Economics
Sissetulek	-217K -19M
Müük	86K 86K
Aktsiakasum	-0.29
Kasumimarginaal	-22,540.698
Töötajad	75
EBITDA	-228K -19M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+52.99% upside

Turustatistika
By TradingEconomics
Turukapital	-179M 958M
Eelmine avamishind	13.51
Eelmine sulgemishind	14.35

Uudiste sentiment

By Acuity

40%

60%

131 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

16.59 / 17.17 Toetus ja vastupanu

Pulse Biosciences Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

18. dets 2025, 23:54 UTC

Kuumad aktsiad

Stocks to Watch: Nike, Cassava Sciences, KB Home

18. dets 2025, 23:51 UTC

Tulu

Nike Sales Tick Up in 2Q; China Weakness Persists -- Update

18. dets 2025, 23:39 UTC

Suurimad hinnamuutused turgudel

Cassava Sciences Shares Fall After FDA Places Hold on Epilepsy Drug Trial

18. dets 2025, 22:57 UTC

Omandamised, ülevõtmised, äriostud

TikTok Signs Agreement for Sale of U.S. Unit, Axios Reports, Citing a Memo

18. dets 2025, 21:40 UTC

Tulu

Nike Sales Tick Up, But China Weakness Persists

18. dets 2025, 23:45 UTC

Market Talk

Gold Steady, Supported by Fed Rate-Cut Prospects -- Market Talk

18. dets 2025, 23:37 UTC

Market Talk

Tulu

Nike 2Q Results Fail to Convince Investors of Recovery -- Market Talk

18. dets 2025, 23:36 UTC

Market Talk

Nikkei May Rise, Tracking Wall Street's Rally -- Market Talk

18. dets 2025, 23:03 UTC

Omandamised, ülevõtmised, äriostud

Mitsubishi Materials: Impact on Consolidated Results for FY Ending March 2026 Likely to be Immaterial

18. dets 2025, 23:02 UTC

Omandamised, ülevõtmised, äriostud

Mitsubishi Materials: To Acquire 4,448 Common Shares, 13,771 Preferred Shares of Co.

18. dets 2025, 23:00 UTC

Omandamised, ülevõtmised, äriostud

Mitsubishi Materials: Investment to Strengthen Recovery Network in U.S.

18. dets 2025, 22:59 UTC

Omandamised, ülevõtmised, äriostud

Mitsubishi Materials: Investment to Contribute to Expanding Collection Volume of Secondary Raw Material

18. dets 2025, 22:58 UTC

Omandamised, ülevõtmised, äriostud

SpaceX Could Go Public by Merging With EchoStar. It Isn't a Crazy Idea. -- Barrons.com

18. dets 2025, 22:57 UTC

Omandamised, ülevõtmised, äriostud

Mitsubishi Materials: Elemental USA E-Waste Operates E-Waste Recycling Business in U.S.

18. dets 2025, 22:56 UTC

Omandamised, ülevõtmised, äriostud

Mitsubishi Materials: To Acquire Portion of Shares of Elemental USA E-Waste & ITAD

18. dets 2025, 22:55 UTC

Tulu

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18. dets 2025, 21:59 UTC

Tulu

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18. dets 2025, 21:50 UTC

Market Talk

Tulu

Tech, Media & Telecom Roundup: Market Talk

18. dets 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

18. dets 2025, 21:35 UTC

Tulu

FedEx's Earnings Were Strong. Cost Cuts and Shipment Volume Helped. -- Barrons.com

18. dets 2025, 21:31 UTC

Tulu

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18. dets 2025, 21:15 UTC

Tulu

Nike 2Q Europe, Middle East & Africa Rev $3.39B >NKE

18. dets 2025, 21:15 UTC

Tulu

Nike 2Q Greater China Rev Down 17% >NKE

18. dets 2025, 21:15 UTC

Tulu

Nike 2Q EPS 53c >NKE

18. dets 2025, 21:15 UTC

Tulu

Nike 2Q Apparel Rev $3.91B >NKE

18. dets 2025, 21:15 UTC

Tulu

Nike 2Q Equipment Rev $550M >NKE

18. dets 2025, 21:15 UTC

Tulu

Nike 2Q N Amer Rev $5.63B >NKE

18. dets 2025, 21:15 UTC

Tulu

Nike 2Q Footwear Rev $7.66B >NKE

18. dets 2025, 21:15 UTC

Tulu

Nike 2Q Asia Pacific & Latin America Rev Down 4% >NKE

18. dets 2025, 21:15 UTC

Tulu

Nike 2Q Greater China Rev $1.42B >NKE

Võrdlus sarnastega

Hinnamuutus

Pulse Biosciences Inc Prognoos

Hinnasiht

By TipRanks

52.99% tõus

12 kuu keskmine prognoos

Keskmine 22 USD 52.99%

Kõrge 22 USD

Madal 22 USD

Põhineb 1 Wall Streeti analüütiku instrumendi Pulse Biosciences Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

1 ratings

Osta

Hoia

Müü

Põhineb 1 analüütiku instrumendi Pulse Biosciences Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

16.59 / 17.17Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Sentiment

By Acuity

131 / 374 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Pulse Biosciences Inc

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.